BioSpace News Archive

Business

Cardior Appoints Cardiac Disease and RNA Drug Development Experts to its Scientific Advisory Board Supporting Pipeline Expansion in Both Large and Orphan Cardiac Indications

Cardior Pharmaceuticals announced the expansion of its Scientific Advisory Board with four newly appointed cardiology and RNA drug development experts.

March 2, 2022
·
4 min read
Biotech Beach

Arcutis to Present at Upcoming Investor Conference - Mar 02, 2022

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.

March 2, 2022
·
2 min read
Genetown

Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness

Flagship Pioneering unveiled Vesalius Therapeutics, a company focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.

March 2, 2022
·
6 min read
Pharm Country

Teleflex to Present at the 43rd Annual Raymond James Institutional Investors Conference

Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 8, 2022, at 9:15 a.m. (ET).

March 2, 2022
·
1 min read
FDA

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women

Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06482077 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA).

March 2, 2022
·
9 min read
Business

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company

ALX Oncology Holdings Inc. today announced the first patient has been dosed in the Phase 2/3 ASPEN-06 study evaluating the combination of evorpacept, a next generation CD47 blocker, and CYRAMZA ® (ramucirumab).

March 2, 2022
·
5 min read
Business

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022

Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial markets on Tuesday, March 15, 2022.

March 2, 2022
·
2 min read
ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

ProMIS Neurosciences, Inc. announced that PMN310, its lead antibody therapeutic candidate for Alzheimer’s disease, showed a significant cognitive benefit in a widely recognized animal model of AD.

March 2, 2022
·
4 min read
Business

IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022 2021 revenue increased 66% over prior year period

IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021.

March 2, 2022
·
9 min read
Genetown

Kymera Therapeutics to Participate in Upcoming March 2022 Investor Conferences

Kymera Therapeutics, Inc. announced that the Company will participate in the following upcoming virtual investor conferences:

March 2, 2022
·
1 min read